The Ph.D. in Pharmaceutics at NIPER Guwahati is a 3-year (minimum) full-time doctoral programme offered by the Department of Pharmaceutics. The programme focuses on advanced drug delivery systems, novel formulation development, nanotechnology-based drug delivery, biopharmaceutics, and pharmaceutical technology. NIPER Guwahati, ranked 12th in the NIRF Pharmacy category, is an Institute of National Importance under the Department of Pharmaceuticals, Government of India. Admission is through NIPER JEE or through Direct PhD admission for candidates with valid national fellowships (CSIR-UGC JRF, DBT JRF, ICMR JRF, DST-INSPIRE, etc.). The total programme fee is Rs. 3.93 Lakhs for 3 years, and PhD scholars receive a monthly fellowship from their respective awarding agencies. The programme is one of the most popular PhD specialisations at NIPER Guwahati, attracting candidates from across India.
Admissions for the 2026 session are upcoming. NIPER Guwahati conducts two PhD admission routes: (1) NIPER JEE-based admission (exam typically in June), and (2) Direct PhD admission for candidates with valid national fellowships (applications typically invited in October-November). The 2025-26 Direct PhD application deadline was November 17, 2025. For NIPER JEE 2026, applications are tentatively expected in April 2026 with the exam in June 2026.
Key Points:
- The Department of Pharmaceutics at NIPER Guwahati is one of the most active research departments, with expertise in nanoparticle-based drug delivery, liposomes, polymeric systems, and targeted drug delivery.
- PhD scholars with national fellowships (CSIR-UGC JRF, DBT JRF, ICMR JRF, DST-INSPIRE) are eligible for Direct PhD admission without NIPER JEE.
- The programme provides access to advanced formulation laboratories, particle size analysers, zeta potential instruments, lyophilisers, and characterisation equipment.
- NIPER Guwahati has strong collaborations with national and international research organisations and pharmaceutical companies.
- The institute is ranked 12th in the NIRF Pharmacy category (2025), reflecting its strong research output.
Comments